Inoviv develops proteomics-based biomarker tests to support pharmaceutical companies in running clinical trials.
Inoviv’s services include Patient Identification and Stratification, Companion Diagnostics and Treatment Efficacy Monitoring. The company measures more than 50 calibrating molecules per biofluid sample and analyzes 3000 biofluid/tissue samples per day. Their technology uses mass spectrometry-based targeted proteomics to test multiplexed protein, peptide, lipid and metabolite biomarker panels. Mass spectrometryMass spectrometry measures the mass-to-charge ratio of molecules. Inoviv’s uses a triple quadrupole mass spectrometry system.
No more activity to show.